Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MEsHH

Financiado

Cerrado

DNA MEthylation for HPV related disease among women living with HIV

Background: The current screening methods for cervical cancer screening among women living with HIV (WLHIV) have previously shown high sensitivity but poor specificity for the detection of high-grade cervical intraepithelial neopl... ver más

04/09/2020

FUNDACIO INSTITUT...

158K€

Presupuesto del proyecto: 158K€

Líder del proyecto

FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-09-04

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACIO INSTITUT D?INVESTIG...

158.12K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

METHYVIREVOL Virocellular hybrids and epigenomic changes as driving facto... 173K€ Cerrado

METHYLBRECA Study on methylation as risk and prognostic factor for breas... 270K€ Cerrado

VALID-SCREEN Validation of PreCursor M for enhanced Cervical Pre Cancer... 3M€ Cerrado

EPISUSCEPTIBILITY Epigenome and Cancer Susceptibility 3M€ Cerrado

FORECEE Female cancer prediction using cervical omics to individuali... 8M€ Cerrado

EpiPrecise Epigenetic profiling of menstrual blood for precision cancer... 150K€ Cerrado

Duración del proyecto: 29 meses Fecha Inicio: 2018-03-06
Fecha Fin: 2020-09-04

Líder del proyecto

FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Presupuesto del proyecto 158K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Background: The current screening methods for cervical cancer screening among women living with HIV (WLHIV) have previously shown high sensitivity but poor specificity for the detection of high-grade cervical intraepithelial neoplasia (CIN2+), resulting in over-referral for colposcopy and overtreatment of cervical lesions that may have low potential for progression to cancer. Methylation changes of human genes or HPV DNA have been reported early in carcinogenesis but their validation for predicting CIN among WLHIV is lacking. Objectives: Among 1238 WLHIV enrolled in Burkina Faso (BF; n=615) and South Africa (SA; n=623), the MesHH study aims to evaluate the performance of the DNA methylation of human genes (CADM1, MAL, MiR and EPB41L3) and HPV (HPV16/18/31/33) for the detection of prevalent and incident CIN2+ compared to, or in combination with, other screening methods (visual inspection using acetic acid [VIA] or Lugol’s iodine [VILI], cytology and HPV DNA) and to evaluate the capacity of the DNA methylation markers to distinguish cervical lesion progression, persistence or regression at 16 months follow-up. Methods: The study will use endocervical swabs with matching histological data collected as part of a prospective study evaluating cervical cancer screening strategies among WLHIV in BF and SA. The DNA methylation assays for human genes (CADM1, MAL, MiR, EPB41L3) and HPV (HPV16/18/31/33) will be performed using pyrosequencing assays. Sensitivity, specificity, positive and negative predictive values for the detection of CIN2+ will be estimated for the various DNA methylation markers, as stand-alone or multiplex tests. Relevance: Multiplex DNA methylation assays including a combination of human genes and HPV virus may have potential as primary screening for CIN2+ among WLHIV. DNA methylation assays also have the potential to be performed using the same clinician- or self-collected sample used for cytology or HPV testing, thereby increasing screening coverage.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores